Zydus Cadila will get EIR from USFDA for Pharma SEZ plant at Ahmedabad

The plant had completed the United States Food and Drug Administration (USFDA) audit from January 16-24, 2017, Zydus Cadila said in a statement.The guarana plant had completed the U . s . States Fda (USFDA) audit from The month of january 16-24, 2017, Zydus Cadila stated inside a statement.
NEW DELHI: Drug firm Zydus Cadila today stated it’s received establishment inspection report in the US health regulator because of its factory at Pharma SEZ at Ahmedabad.

The guarana plant had completed the U . s . States Fda (USFDA) audit from The month of january 16-24, 2017, Zydus Cadila stated inside a statement.

The business’s “formulations factory at Pharma SEZ, Ahmedabad has gotten an institution Inspection Report (EIR) in the USFDA signifying the effective closure from the audit”, it added.

Shares of Cadila Healthcare, the listed entity of Zydus Group were today buying and selling at Rs 499.75 per scrip within the mid-day trade on BSE, lower .26 percent in the previous close.

Leave a Reply

Your email address will not be published. Required fields are marked *